# Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)

> **NCT05159570** · NA · COMPLETED · sponsor: **University of Aarhus** · enrollment: 10 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Diabetes Mellitus, Type 2
- Ketonemia

## Interventions

- **DIETARY_SUPPLEMENT:** Ketone ester
- **DIETARY_SUPPLEMENT:** Placebo drink

## Key facts

- **NCT ID:** NCT05159570
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-01
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05159570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05159570, "Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05159570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*